Assignee
SHATTUCK LABS INC
US·21 granted patents·31 pending applications·43 citations·filing 2018–2025
Top patents by PatentIndex Score
52 records- 0197US10988517B2Heterodimeric proteins for modulating gamma delta T cellsSHATTUCK LABS INC·Filed 2020·Granted Apr 27, 2021·4 cites·18 claims
- 0296US11834488B2VSIG8-based chimeric proteinsSHATTUCK LABS INC·Filed 2021·Granted Dec 5, 2023·2 cites·19 claims
- 0396US11643447B2Heterodimeric proteins for modulating gamma delta T cellsSHATTUCK LABS INC·Filed 2022·Granted May 9, 2023·2 cites·19 claims
- 0496US10899817B2TIGIT- and light-based chimeric proteinsSHATTUCK LABS INC·Filed 2020·Granted Jan 26, 2021·3 cites·20 claims
- 0595US10995127B2Heterodimeric proteins and uses thereofSHATTUCK LABS INC·Filed 2019·Granted May 4, 2021·8 cites·14 claims
- 0694US12319742B1Antibodies that bind TNFRSF25SHATTUCK LABS INC·Filed 2025·Granted Jun 3, 2025·1 cites·17 claims
- 0794US11780897B2Heterodimeric proteins and uses thereofSHATTUCK LABS INC·Filed 2021·Granted Oct 10, 2023·2 cites·20 claims
- 0894US10927159B2TIGIT- and light-based chimeric proteinsSHATTUCK LABS INC·Filed 2020·Granted Feb 23, 2021·2 cites·26 claims
- 0993US11896618B2FLT3L-based chimeric proteinsSHATTUCK LABS INC·Filed 2020·Granted Feb 13, 2024·2 cites·3 claims
- 1091US11098093B2Heterodimeric proteins for modulating gamma delta T cellsSHATTUCK LABS INC·Filed 2020·Granted Aug 24, 2021·2 cites·16 claims
- 1190US11332509B2Methods of making and using extracellular domain-based chimeric proteinsSHATTUCK LABS INC·Filed 2018·Granted May 17, 2022·2 cites·20 claims
- 1290US10513548B2CSF1R-based chimeric proteinsSHATTUCK LABS INC·Filed 2018·Granted Dec 24, 2019·3 cites·16 claims
- 1389US12492236B2Fusion proteins for the treatment of cardiometabolic diseasesSHATTUCK LABS INC·Filed 2024·Granted Dec 9, 2025·0 cites·6 claims
- 1489US2024368242A1Methods of making and using extracellular domain-based chimeric proteinsSHATTUCK LABS INC·Filed 2024·Application pending·0 cites
- 1588US12145975B2Fusion proteins for the treatment of cardiometabolic diseasesSHATTUCK LABS INC·Filed 2024·Granted Nov 19, 2024·0 cites·1 claims
- 1688US11267857B2CSF1R-based chimeric proteinsSHATTUCK LABS INC·Filed 2019·Granted Mar 8, 2022·2 cites·18 claims
- 1788US11192934B2VSIG8-based chimeric proteinsSHATTUCK LABS INC·Filed 2019·Granted Dec 7, 2021·2 cites·10 claims
- 1888US2024190939A1Tigit- and light-based chimeric proteinsSHATTUCK LABS INC·Filed 2024·Application pending·0 cites
- 1987US11267856B2CSF1R-CD40L chimeric proteinsSHATTUCK LABS INC·Filed 2018·Granted Mar 8, 2022·2 cites·14 claims
- 2087US10780121B2FLT3L-based chimeric proteinsSHATTUCK LABS INC·Filed 2019·Granted Sep 22, 2020·2 cites·7 claims
- 2187US2025066446A1Fusion proteins for the treatment of cardiometabolic diseasesSHATTUCK LABS INC·Filed 2024·Application pending·0 cites
- 2287US2025145681A1Fusion proteins for the treatment of cardiometabolic diseasesSHATTUCK LABS INC·Filed 2024·Application pending·0 cites
- 2386US11192933B2VSIG8-based chimeric proteinsSHATTUCK LABS INC·Filed 2018·Granted Dec 7, 2021·2 cites·10 claims
- 2484US2024067698A1Vsig8-based chimeric proteinsSHATTUCK LABS INC·Filed 2023·Application pending·0 cites
- 2583US12071465B2Methods of making and using extracellular domain-based chimeric proteinsSHATTUCK LABS INC·Filed 2022·Granted Aug 27, 2024·0 cites·20 claims
- 2681US2022227831A1Tigit- and light-based chimeric proteinsSHATTUCK LABS INC·Filed 2022·Application pending·0 cites
- 2777US2023220030A1Heterodimeric proteins and uses thereofSHATTUCK LABS INC·Filed 2023·Application pending·0 cites
- 2876US2022144909A1Csf1r-based chimeric proteinsSHATTUCK LABS INC·Filed 2022·Application pending·0 cites
- 2973US12460010B2Antibodies that bind TNFRSF25SHATTUCK LABS INC·Filed 2025·Granted Nov 4, 2025·0 cites·14 claims
- 3071US2024011101A1Method of determining resistance to checkpoint inhibitor therapiesSHATTUCK LABS INC·Filed 2021·Application pending·0 cites
- 3171US2024016892A1Methods of treating cancer using tigit-and light-based chimeric proteinsSHATTUCK LABS INC·Filed 2021·Application pending·0 cites
- 3268US2023045794A1Nk cell-directed chimeric proteinsSHATTUCK LABS INC·Filed 2022·Application pending·0 cites
- 3368US2024122983A1Flt3l-based chimeric proteinsSHATTUCK LABS INC·Filed 2023·Application pending·0 cites
- 3465US2021379153A1Combination therapies comprising sirp alpha-based chimeric proteinsSHATTUCK LABS INC·Filed 2019·Application pending·0 cites
- 3565US2022025000A1Heterodimeric proteins for modulating gamma delta t cellsSHATTUCK LABS INC·Filed 2021·Application pending·0 cites
- 3665US2021309744A1Combination therapies comprising pd-1-based chimeric proteinsSHATTUCK LABS INC·Filed 2019·Application pending·0 cites
- 3762US2020399344A1Nk cell-directed chimeric proteinsSHATTUCK LABS INC·Filed 2020·Application pending·0 cites
- 3862US2025223313A1Methods of contaminant removal from protein isolatesSHATTUCK LABS INC·Filed 2023·Application pending·0 cites
- 3961US2023048633A1Tgfbr2-based chimeric proteinsSHATTUCK LABS INC·Filed 2022·Application pending·0 cites
- 4060US2024141014A1Mutant pd-1 extracellular domainsSHATTUCK LABS INC·Filed 2022·Application pending·0 cites
- 4160US2024299492A1Combination therapies with sirp alpha-based chimeric proteinsSHATTUCK LABS INC·Filed 2022·Application pending·0 cites
- 4258US2023408523A1Methods of identifying gamma delta t cell-modulating agentsSHATTUCK LABS INC·Filed 2021·Application pending·0 cites
- 4358US2024148828A1Gamma delta t-cell costimulationSHATTUCK LABS INC·Filed 2022·Application pending·0 cites
- 4456US2023416333A1Homodimeric and heterodimeric proteins comprising butyrophilinSHATTUCK LABS INC·Filed 2021·Application pending·0 cites
- 4555US2025345406A1Chimeric proteins in autoimmunitySHATTUCK LABS INC·Filed 2022·Application pending·0 cites
- 4654US2021179689A1Combination therapies comprising tim-3-based chimeric proteinsSHATTUCK LABS INC·Filed 2019·Application pending·0 cites
- 4754US2021324041A1Combination therapiesSHATTUCK LABS INC·Filed 2019·Application pending·0 cites
- 4853US2022259281A1Chimeric protein expressing t-cellsSHATTUCK LABS INC·Filed 2020·Application pending·0 cites
- 4952US2025320268A1Clinical dosing of sirp1a chimeric proteinSHATTUCK LABS INC·Filed 2021·Application pending·0 cites
- 5051US2022185863A1Combination therapiesSHATTUCK LABS INC·Filed 2020·Application pending·0 cites
Showing the top 50 of 52 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when SHATTUCK LABS INC files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →